US 12,203,098 B2
Cells having solid tumor targeting backbone and use thereof
Bahram Valamehr, San Diego, CA (US); Tom Tong Lee, San Diego, CA (US); Martin Hosking, San Diego, CA (US); Eigen Peralta, San Diego, CA (US); and Chia-Wei Chang, San Diego, CA (US)
Assigned to FATE THERAPEUTICS, INC., San Diego, CA (US)
Filed by FATE THERAPEUTICS, INC., San Diego, CA (US)
Filed on Jun. 30, 2023, as Appl. No. 18/345,885.
Application 18/345,885 is a continuation of application No. PCT/US2023/065550, filed on Apr. 7, 2023.
Claims priority of provisional application 63/380,378, filed on Oct. 20, 2022.
Claims priority of provisional application 63/329,364, filed on Apr. 8, 2022.
Prior Publication US 2023/0357716 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/078 (2010.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01)
CPC C12N 5/0634 (2013.01) [A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/3015 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)] 30 Claims
 
1. A cell or a population thereof, wherein
(i) the cell is (a) an immune cell; (b) an induced pluripotent cell (iPSC); or (c) a derivative effector cell obtained from differentiating the iPSC; and
(ii) the cell comprises a polynucleotide encoding a chimeric antigen receptor (CAR) comprising:
(a) an ectodomain comprising an antigen binding domain recognizing a HER2 (human epidermal growth factor receptor 2) antigen, wherein the antigen binding domain comprises:
(1) a heavy chain variable (VH) domain comprising a heavy chain complementary determining region 1 (H-CDR1) comprising SEQ ID NO: 103, a heavy chain complementary determining region 2 (H-CDR2) comprising SEQ ID NO: 104, and a heavy chain complementary determining region 3 (H-CDR3) comprising SEQ ID NO: 105; and
(2) a light chain variable (VL) domain comprising a light chain complementary determining region 1 (L-CDR1) comprising SEQ ID NO: 106, a light chain complementary determining region 2 (L-CDR2) comprising SEQ ID NO: 107, and a light chain complementary determining region 3 (L-CDR3) comprising SEQ ID NO: 108;
(b) a transmembrane domain; and
(c) an endodomain comprising at least one signaling domain;
wherein the at least one signaling domain responds specifically to binding of the CAR to a HER2 antigen expressed on a cancer cell.